Home
Latest
Finance
IPO
ETF
Tech
Overseas
Video
Research
Topic
Download App
简
繁
简
繁
EN
Home
Latest
Finance
IPO
ETF
Tech
Overseas
Video
Research
Topic
HOME
·
01276.HK
Hengrui Pharmaceuticals(01276.HK): Concentrated Solution for Injection HRS-8829 Receives Clinical Trial Approval Notice
Tags:
Hengrui Pharmaceuticals
01276.HK
2026-07-15
Hengrui Pharmaceuticals(01276.HK): Injection SHR-3079 Obtains Clinical Trial Approval Notice
Tags:
Hengrui Pharmaceuticals
01276.HK
2026-07-13
HENGRUI PHARMA (01276.HK): Receives CRL from FDA for Camrelizumab Liver Cancer Indication, Related to cGMP Inspection Findings at Apatinib Manufacturing Site
Tags:
HENGRUI PHARMA
01276.HK
Pharmaceutical Updates
2026-07-10
HENGRUI PHARMA (01276.HK): SHR-4685 Injection Obtains Clinical Trial Approval for Advanced Solid Tumours
Tags:
HENGRUI PHARMA
01276.HK
Clinical Trial Application
2026-07-07
Hengrui Medicine (01276.HK) Adebrelimab Becomes First Domestic PD-L1 Inhibitor for NSCLC Perioperative Setting
Tags:
Hengrui Medicine
01276.HK
A+H
2026-06-25
Hengrui Medicine (01276.HK): Marketing Authorization Application for Relugolix Tablets Accepted by EMA
Tags:
Hengrui Medicine
01276.HK
2026-06-22
Hengrui Medicine (01276.HK): SHR-6914 Injection Approved for Clinical Trials
Tags:
Hengrui Medicine
01276.HK
2026-06-16
Hengrui Pharma (01276.HK): Enters Global Strategic Collaboration with Bristol Myers Squibb, Total Transaction Value Up to ~US$15.2 Billion
Tags:
HENGRUI PHARMA
01276.HK
Strategic Collaboration
2026-05-12
HENGRUI PHARMA (01276.HK): Five Innovative Drugs Obtain Clinical Trial Approvals, Targeting KRAS G12D and Other Indications
Tags:
HENGRUI PHARMA
01276.HK
Notice of Approval for Clinical Trials
2026-05-09
HENGRUI PHARMA(01276.HK): HRS-3005 Tablets Granted Clinical Trial Approval for B-Cell Malignancies
Tags:
HENGRUI PHARMA
01276.HK
Notice of Approval for Clinical Trials
2026-05-09
HENGRUI PHARMA(01276.HK): 2026 Q1 Report - Profit Attributable to Shareholders stood at CNY 2.28 billion, YoY increase of 21.78%
Tags:
HENGRUI PHARMA
01276.HK
financials
2026-04-23
HENGRUI PHARMA(01276.HK): Receives Clinical Trial Approval for SHR-1049 Injection, Targeting Advanced Solid Tumors
Tags:
HENGRUI PHARMA
01276.HK
2026-01-26
Previous
1
2
3
Finance
METIS TECHBIO-P (07666.HK): plans H-share buyback of up to HKD 300m
Finance
HENGRUI PHARMA (01276.HK): hetrombopag NDA accepted in China
Research
HK Stock Connect Daily: NETEASE -17.60% on Gaming Slump - 20261120
Finance
WATER OASIS GP (01161.HK): FY profit seen doubling to HKD 165-175m
Research
HK AI Concept Stock Daily: BABA-W +3.48% Defies Slump - 20261120
Research
Hong Kong Recently Listed Stocks Daily Report: BRAINAURORA-B Rises 39.50% to Lead; Intelligent Driving and Smart Parking Gain Traction-20261120
Finance
NewTimeSpace | HK Close: HSI -1.89%, Semis and Hardware Lead Declines
Research
HK shares ETFs Daily Report: Fubon Taiwan Semiconductor ETF Falls 9.81% as CSI 300 and India Themes Rise-Nov 20, 2026
Research
Offshore Trust Insight | NIO-SW (09866.HK) -5.07%; Users Trust 50m
Research
HK Stock Connect Insight | RA MATERIALS (09607.HK) -13.26%; Stake Rise
Scan QR Code
Download App